However, using a FGM system to investigate glycemic control and GV in poorly controlled type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 (GLP-1) analog in combination with continuous subcutaneous insulin infusion (CSII) therapy is rare. This evidence concerns the gene INS and diabetes mellitus.